NHS cancer waiting times hit record high amid staff crisis

More than 60 per cent of cancer patients in England are waiting longer than the NHS's own 62-day target from urgent referral to treatment, according to NHS England performance data — a record proportion that clinicians and patient advocates say is placing lives at risk. The figures, released amid warnings of a deepening workforce crisis across oncology, radiotherapy, and diagnostic services, have renewed calls for urgent structural reform of the health service's cancer care pathway.

The Scale of the Crisis

NHS England data show that the 62-day standard — which requires patients to begin treatment within 62 days of an urgent GP referral for suspected cancer — has not been consistently met since before the Covid-19 pandemic. Performance against this benchmark has deteriorated further in recent periods, with hundreds of thousands of patients affected annually across all tumour types.

According to NHS England figures, approximately 300,000 people are currently waiting for cancer treatment or diagnostic tests at any one time. The longest waits are recorded in urology, lower gastrointestinal, and gynaecological cancers — areas where diagnostic bottlenecks and specialist shortages are most acute, officials said.

This troubling picture mirrors a broader systemic challenge detailed in our coverage of NHS waiting times hitting record highs amid a staff crisis, which examines how workforce shortages are affecting services beyond oncology.

Tumour Types Worst Affected

Lung, colorectal, and bladder cancers are among those with the highest rates of delayed treatment starts, according to NHS performance breakdowns. These are also cancers where early-stage diagnosis is strongly associated with significantly improved survival outcomes. Clinical oncologists have warned that stage migration — patients progressing from an earlier, more treatable stage to a later stage during the wait — is an increasingly documented consequence of systemic delays. (Source: NHS England)

Workforce Pressures Driving Delays

Health workforce analysts and NHS trust executives have identified staff shortages as a primary structural driver of the backlog. The NHS Long Term Workforce Plan, published by NHS England, acknowledged a shortfall of thousands of clinical and support staff across cancer services, including radiographers, oncology nurses, and consultant oncologists.

The Royal College of Radiologists has reported that the UK currently has one of the lowest numbers of clinical oncologists per capita among comparable European health systems. Without sufficient radiotherapy and chemotherapy capacity, patients referred urgently through the two-week-wait pathway frequently encounter secondary bottlenecks once they enter the treatment system. (Source: Royal College of Radiologists)

Diagnostic Capacity Under Strain

Delays are not confined to treatment alone. Diagnostic imaging services — including CT scanning, MRI, and endoscopy — are operating under sustained pressure, with wait times for initial diagnostic tests adding weeks to many patients' pathways. NHS England has invested in community diagnostic centres as part of its elective recovery programme, and early data suggest these are beginning to reduce wait times in some regions, though coverage remains uneven. (Source: NHS England)

The shortage of consultant radiologists and pathologists compounds the problem. A report from the Royal College of Pathologists found that histopathology departments — critical for cancer diagnosis confirmation — are working at or above capacity in many NHS trusts. Workforce planning submissions to the Department of Health and Social Care have flagged this as a medium-term risk to cancer outcomes nationally. (Source: Royal College of Pathologists)

What the Evidence Says About Delayed Cancer Treatment

The clinical evidence base for the impact of treatment delays on cancer survival is well established and consistently cited by NHS clinicians and researchers.

A landmark analysis published in The Lancet found that for most solid tumour types, each four-week delay in treatment is associated with an approximately 6 to 13 per cent increase in mortality risk, depending on cancer type. For faster-growing tumours such as certain lung and ovarian cancers, this risk gradient is steeper. (Source: The Lancet)

Research published in the BMJ has further demonstrated that delays in the diagnostic phase — before treatment even begins — carry comparable mortality risks to delays in treatment delivery. The researchers concluded that systemic pathway improvements, rather than piecemeal interventions, are required to produce population-level improvements in survival. (Source: BMJ)

Stage at Diagnosis Remains a Key Determinant

The World Health Organization consistently identifies stage at diagnosis as the single most powerful predictor of cancer survival across most tumour types. According to WHO data, patients diagnosed at stage one or two have survival rates that are, on average, two to four times higher than those diagnosed at stage three or four. When waiting times extend the interval between symptom onset and treatment, stage migration becomes a clinically significant concern, experts say. (Source: WHO)

NHS Targets, NICE Guidance, and Policy Context

NICE guidelines stipulate that patients referred by a GP with suspected cancer should be seen by a specialist within two weeks. This two-week-wait standard is the first gate in a system designed to achieve the 62-day referral-to-treatment target. However, performance data show that both targets are frequently breached, with regional variation significant — patients in some parts of England waiting substantially longer than those in others. (Source: NICE)

NHS England's ten-year cancer plan, currently in development, is expected to set ambitious new targets for early diagnosis, with a stated ambition to diagnose 75 per cent of cancers at stage one or two. Achieving this will require not only workforce expansion but structural reform of the referral pathway, including greater use of non-GP referral routes and expanded community screening programmes, officials said.

For a detailed examination of how funding constraints are compounding these pressures, see our reporting on NHS cancer waiting times hitting record highs amid a funding squeeze.

Regional Inequality in Cancer Care

Analysis of NHS England performance data by region reveals significant inequalities in access to timely cancer diagnosis and treatment. Trusts in the North of England and parts of the Midlands consistently report lower performance against the 62-day standard than London and the South East, a disparity linked to differences in consultant workforce density, diagnostic infrastructure, and deprivation levels. Cancer Research UK has described this geographic variation as one of the most pressing equity challenges in UK healthcare. (Source: Cancer Research UK)

What Patients Should Know: Recognising Warning Signs

Public health officials and cancer charities emphasise that patients who are aware of potential warning signs and seek medical attention promptly are more likely to be diagnosed at an earlier, more treatable stage. The following symptoms should prompt a consultation with a GP without delay, according to NHS and NICE guidance:

• Unexplained weight loss over several weeks without a change in diet or activity
• A persistent cough lasting more than three weeks, particularly with blood in sputum
• Unexplained bleeding, including blood in urine, stool, or abnormal vaginal bleeding
• A new lump or swelling anywhere on the body, or a change to an existing lump
• Persistent bloating, particularly in women, which may indicate ovarian pathology
• Difficulty swallowing or persistent indigestion unresponsive to standard treatment
• A sore or ulcer in the mouth that does not heal within three weeks
• Changes in bowel habits persisting for more than three weeks without explanation
• Fatigue that is severe and unexplained, particularly when combined with other symptoms
• A mole that changes in size, shape, colour, or begins to bleed

NHS guidance advises patients not to self-diagnose but to contact their GP promptly if any of these symptoms are present. GPs are required under NICE guidelines to refer patients with high-risk features via the urgent two-week-wait pathway. (Source: NHS, NICE)

The Path Forward

Health policy analysts broadly agree that resolving the cancer waiting times crisis will require simultaneous action on multiple fronts: accelerating workforce training pipelines, expanding diagnostic infrastructure, reforming referral pathways, and addressing the upstream social determinants that delay symptom presentation. Short-term capacity measures — including extended operating hours, independent sector partnerships, and community diagnostic centre expansion — offer partial relief but are not sufficient substitutes for sustained structural investment, experts say.

For broader context on how staff shortages are affecting the wider NHS system, our ongoing coverage of NHS waiting times hitting record highs as staff shortages worsen provides further analysis across multiple specialties.

Patient organisations, including Macmillan Cancer Support and Cancer Research UK, have called on the government to publish a fully costed cancer workforce strategy that addresses both immediate vacancies and long-term training capacity. Without this, clinicians warn, the gap between NHS cancer care ambitions and the lived experience of patients will continue to widen — with measurable consequences for survival rates that are already below the European average for several major tumour types. (Source: Macmillan Cancer Support, Cancer Research UK)

The Department of Health and Social Care said it remains committed to improving cancer outcomes and that investment in community diagnostic centres and the NHS workforce plan represents a significant step toward meeting its early diagnosis targets. Independent analysts, however, caution that the scale of the current backlog and the depth of workforce shortages mean meaningful improvement in waiting time performance is unlikely to materialise rapidly without additional, targeted resource allocation.